{"doi":"10.1016/j.ebiom.2020.102900","title":"Blood speaks: Personalised medicine profiling for heart failure patients","abstract":"Heterogeneity in patient populations caused by factors such as age, genetic background, and clinical condition confound prognostication efforts toward treatment efficacy of coronary artery bypass grafting (CABG) surgery. The conundrum of patient heterogeneity has been approached by advances in personalised medicine to develop tailored therapies. Recent biomedical studies search for patient-specific biomarker signatures to effectively predict postoperative results. In this article of EBioMedicine, Wolfien et al. propose a diagnostic strategy to predict the response of CABG surgery patients in terms of myocardial repair induced by bone marrow stem cells (BMSC) [[1]Wolfien M. Klatt D. Salybekov A.A. et al.Hematopoietic stem-cell senescence and myocardial repair - Coronary artery disease genotype / phenotype analysis of post-MI myocardial regeneration response induced by CABG / CD133 + bone marrow hematopoietic stem cell treatment in RCT PERFEC.EBioMedicine. 2020; https://doi.org/10.1016/j.ebiom.2020.102862Summary Full Text Full Text PDF PubMed Scopus (2) Google Scholar]. Predictive analyses in such a scenario would provide much needed information to identify those individuals most likely to benefit from BMSC treatment with patient-specific diagnostic characteristics. Over the past decade a substantial amount of effort has been expended upon BMSCs transplantation with concomitant CABG surgery with the goal of leveraging synergistic paracrine, angiogenic and, anti-inflammatory effect of the cells to promote recovery. Collective results demonstrate autologous CD133+ BMSC transplantation combined with CABG surgery is a safe cellular intervention strategy, albeit with highly debated efficacy. Despite outcome variability, recent randomised multicenter trials with large patient populations such as phase II IMPACT-CABG [[2]Noiseux N. Mansour S. Weisel R. et al.The IMPACT-CABG trial: a multicenter, randomized clinical trial of CD133+ stem cell therapy during coronary artery bypass grafting for ischemic cardiomyopathy.J Thorac Cardiovasc Surg. 2016; 152 (Mosby Inc): 1582-1588Summary Full Text Full Text PDF PubMed Scopus (26) Google Scholar], phase III PERFECT [[3]Steinhoff G. Nesteruk J. Wolfien M. et al.Cardiac function improvement and bone marrow response-outcome analysis of the randomized PERFECT phase III clinical trial of intramyocardial CD133 + application after myocardial infarction the PERFECT trial investigators group.EBioMedicine. 2017; 22: 208-224Summary Full Text Full Text PDF PubMed Scopus (29) Google Scholar] and phase II/III COMPARE CPM-RMI [[4]Hassan Naseri M., Madani H., Hossein Ahmadi Tafti S., et al. COMPARE CPM-RMI Trial: intramyocardial transplantation of autologous bone marrow-derived CD133 + Cells and MNCs during CABG in patients with recent MI: a phase II/III, multicenter, placebo-controlled, randomized, double-blind clinical trial. Cell Jn.d. 2018;20:267–77.Google Scholar] reported significant improvement in left ventricle ejection fraction (LVEF) in CD133+BMSC recipients compared to the placebo group (CABG only). Meta-analyses accumulating large patient cohorts in randomised controlled trials (RCTs) confirmed an overall improvement in LVEF in response to BMSC treatment [[5]Ayyat K.S. Argawi A. Mende M. et al.Combined coronary artery bypass surgery with bone marrow stem cell transplantation: are we there yet?.Ann Thorac Surg. 2019; 108: 1913-1921Summary Full Text Full Text PDF PubMed Scopus (5) Google Scholar,[6]Wu S. Yao L. Yan P. et al.Autologous bone marrow stem cell therapy for patients undergoing coronary artery bypass grafting: a meta-analysis of 14 randomized controlled trials.Exp Ther Med. 2019; 17: 2985-2994PubMed Google Scholar]. Confoundingly, clinically relevant improvement of LV function as well as non-responsiveness were both reported in BMSC/CABG recipients and the placebo/CABG group. Regardless of treatment, approximately 40% of patients were not responsive to the therapy [[5]Ayyat K.S. Argawi A. Me","journal":"EBioMedicine","year":2020,"id":114055,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9512,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":363506,"name":"Mark A. Sussman","orcid":"0000-0002-0104-4799","position":1,"is_corresponding":false},{"id":363501,"name":"Fareheh Firouzi","orcid":"0000-0002-5931-2717","position":0,"is_corresponding":true}],"reference_count":11,"raw_metadata":null,"created_at":"2026-07-18T23:13:25.964732Z","pmid":"32711252","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}